Prof. Gian Maria Rossolini joins the Scientific Advisory Board at Gradientech
The diagnostics company Gradientech today announces that Prof. Gian Maria Rossolini, Professor of Microbiology and Clinical Microbiology at the University of Florence, joins as a new member of the company’s prominent international Scientific Advisory Board.
Gian Maria Rossolini is Professor of Microbiology and Clinical Microbiology at the University of Florence, and Director of the Microbiology and Virology Unit at Florence Careggi University Hospital. Gian Maria Rossolini has served as member of the Editorial Board of several international journals dedicated to Clinical Microbiology and Antimicrobial Chemotherapy. His main research interests focus on antimicrobial agents, microbial drug resistance and diagnostic microbiology.
“Prof. Rossolini is a highly respected and well-renowned leader in the field of microbiology, and we are honoured to welcome him to our Scientific Advisory Board. His broad expertise in antimicrobial agents, microbial drug resistance mechanisms, and rapid antimicrobial susceptibility testing will significantly contribute to our scientific and clinical discussions,” says Sara Thorslund, co-founder and CEO at Gradientech.
“I am truly honoured to join as scientific advisor for a company developing innovative diagnostic technologies, and I am looking forward to exciting scientific discussions in the area of rapid antimicrobial susceptibility testing, due to the potential clinical relevance of these systems”, says Gian Maria Rossolini, new member of the Scientific Advisory Board at Gradientech.
The ultra-rapid and precise antibiotic susceptibility testing results of QuickMIC® contribute to timely and effective management of sepsis patients, helping clinicians make faster antibiotic treatment decisions. Its modular design offers affordable scaling possibilities, making QuickMIC suitable for both small and large hospital laboratories. QuickMIC and its gram-negative panel are CE marked and commercially available in Europe but not yet available for sale in the United States.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
About Gradientech
Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, contributes to the effective management of sepsis patients by supporting antibiotic treatment decisions in record time. This helps save lives, reduce healthcare costs, and combat the spread of antibiotic resistance – one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.